Albemarle expands South Haven API production site

Tuesday, July 10, 2012 11:19 AM

Albemarle, a global developer, manufacturer and marketer of highly engineered specialty chemicals, has begun upgraded and expanded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Mich.

This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios.  In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status. 

Production using the new expanded capacity commenced on June 1, 2012. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs